An observational study in Atypical Hemolytic Uremic Syndrome (aHUS), sponsored by Alexion Pharmaceuticals, Inc.. Completed at 23 sites in 8 countries. Per ClinicalTrials.gov, last updated 2023-08-18.
Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Atypical Hemolytic Uremic Syndrome by AstraZeneca — 4 open to participants now, 5 under way, none of them phase 3. Atypical Hemolytic Uremic Syndrome · AstraZeneca.
Among the 19 studies in Atypical Hemolytic Uremic Syndrome by AstraZeneca, this one is one of 5 that started in 2009, is one of 9 observational ones, and was the 9th registered.
45 studies on the registry are indexed under Atypical Hemolytic Uremic Syndrome; 14 are open to participants now.
Browse Atypical Hemolytic Uremic Syndrome studies →4 of the 19 studies in Atypical Hemolytic Uremic Syndrome by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Poland
Ages 18+
Alexion Pharmaceuticals, Inc. · Sites in Japan
Ages 18+
Alexion Pharmaceuticals, Inc. · Sites in United States, Australia, France and 4 more countries
Women only
Alexion Pharmaceuticals, Inc. · Sites in United States, Australia, Belgium and 14 more countries
By country, each count listing its studies:
Of the 12 Atypical Hemolytic Uremic Syndrome studies recruiting now, 10 (83%) set no upper age limit and none (0%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 5 started in 2009.
This study's enrollment of 30 is below the median of 80 across 15 observational studies indexed under Atypical Hemolytic Uremic Syndrome.
Median enrollment 18 across the 10 interventional studies, 80 across the 9 observational. Of the 14 that completed or were terminated, 9 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Alexion Pharmaceuticals, Inc., one of the names counted as AstraZeneca. Under that name alone:
Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.
Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.
1 of the studies in Atypical Hemolytic Uremic Syndrome by AstraZeneca that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07308574Alexion Pharmaceuticals, Inc.Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS | 2027-06-25 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies in Atypical Hemolytic Uremic Syndrome by AstraZeneca, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this retrospective trial is to assess safety and efficacy of eculizumab in aHUS patients treated outside of an Alexion-sponsored controlled clinical trial.
Male or female patients of any age who have been diagnosed with aHUS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Overall safety and tolerability of eculizumab based on Adverse Events of Special Interest/Adverse Drug Reactions and Additional Adverse Events.
Time frame: Through 26 weeks
Assess eculizumab treatment affect based on change in laboratory parameters (platelets, hemoglobin, LDH and parameters associated with renal function and intravascular hemolysis) and reduction of thrombotic microangiopathy (TMA).
Time frame: Through 26 weeks
Ran from Aug 2009 to primary completion in Nov 2010, 14 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Atypical Hemolytic Uremic Syndrome →
Alexion Pharmaceuticals, Inc. →